The firm said that its Verigene II multiplex system is on track to launch in mid-2020 among a number of new products scheduled for release this year.
The system showed good performance for cervical samples as well as orophyrengeal samples, and required no extraction step.
The diagnostic firms were the final companies in the coverage universe of 360Dx to present at the annual conference.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
The UK firm has purchased the assets for Enigma Diagnostics and anticipates it will soon receive clearance to market its first test for TB in China.
The firm will use the new funds to accelerate development of products, expand partnerships, and support commercialization of its two multiplex panels.
The firm said that in its product pipeline in 2019 it focused on organ transplant and lung health, involving use of its multiplexed research-use TORdx Lung tests.
The test detects 20 common viruses and bacteria that cause upper respiratory infections using the firm's high-throughput, automated MDx-3000 instrument.
The firm moved closer to commercializing its lung transplant test, and it was notified by New York State that it could begin testing patient samples using its DTC celiac disease test.
The clearance of the Binx io CT/NG test marks a milestone for the Johns Hopkins University group that funds early-stage development of rapid STI testing.